Pathalys secures $105m to advance SHPT drug through approval
Pathalys Pharma has secured $105m in a Series B financing round to support its clinical trials, file a new drug…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
-
-
J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC
Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) has secured US Food and Drug Administration (FDA) approval as a…
-
DeepCure links with Leeds Institute to bring AI-based RA drug to clinic
Massachusetts Institute of Technology-spinout DeepCure has teamed up with the Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) to advance…
-
AstraZeneca wins approval for Imfinzi in NSCLC perioperative setting
AstraZeneca’s Imfinzi (durvalumab) plus chemotherapy has secured US Food and Drug Administration (FDA) approval for non-small cell lung cancer (NSCLC)…
-
US government unveils finalised drug prices under Inflation Reduction Act
The US government has finalised prices for the first ten drugs negotiated under the Inflation Reduction Act (IRA), marking a…
-
Evotec slashes workforce by 400 people in “difficult market”
German life science company Evotec is cutting 400 jobs as the company continues to deal with ‘a more difficult market…
-
Kezar stalls solid tumour trial to focus on autoimmune disease candidate
Clinical stage biopharma Kezar Life Sciences will drop its Phase I solid tumour drug to streamline focus on its lead…
-
GLP-1 receptor agonists cut risk of death in inflammatory disease patients, says study
Certain diabetes medications such as Novo Nordisk’s Ozempic (semaglutide) reduced the risk of death and heart attacks in patients with…
-
Patient with rare neurodegenerative disorder improves with non-profit’s ASO therapy
A patient with a rare progressive neurodegenerative disorder receiving a personalised experimental antisense oligonucleotide (ASO) treatment developed by the non-profit…
-
NICE supports Theramex’s Eladynos for post-menopause osteoporosis
Theramex’s Eladynos (abaloparatide) will be available for menopausal women with osteoporosis in England within three months, following positive guidance from…